FEBELCOFONDS
ActiveFEBELCOFONDS has been active since 2002 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €8.67M and a net result of €2.84M. Equity is shrinking by ~4.8% per year across the filed fiscal years. The computed 12-month bankruptcy probability is 0.2% (very low).
Checked score
Score 2025
89
/ 100
Excellent
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100▲+33
Solvency100=
Growth58=
Track record100
Bankruptcy probability, 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €750k at 30 days acceptable
Liquidity short (current ratio 0.0 against 0.54 in 2024; short-term debt: 9.9% and cash: 0% of total assets), and 10.5% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
89.5%
Return on assets
29.3%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
31 d late
2024
28 d late
2023
30 d late
2022
31 d late
2021
34 d early
2020
47 d early
2019
39 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
17-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€8.67M▼ 13.4%
2024 · €10.01M
2018: €13.25M
2019: €12.85M
2020: €11.55M
2021: €11.31M
2022: €10.99M
2023: €10.63M
2024: €10.01M
2018 → 2025
Total assets
€9.69M▼ 6.5%
2024 · €10.36M
2018: €13.69M
2019: €13.28M
2020: €12.33M
2021: €12.08M
2022: €11.76M
2023: €11.45M
2024: €10.36M
2018 → 2025
Net result
€2.84M▲ 131%
2024 · €1.23M
2018: €1.01M
2019: €1.52M
2020: €1.03M
2021: €1.33M
2022: €931k
2023: €636k
2024: €1.23M
2018 → 2025
Working capital
€-956k▼ 606%
2024 · €-135k
2018: €91k
2019: €617k
2020: €-124k
2021: €-82k
2022: €-109k
2023: €-114k
2024: €-135k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€11.31M-€10.99M▼ 2.9%€10.63M▼ 3.3%€10.01M▼ 5.8%€8.67M▼ 13.4%
Operating result€-2k-€-2k▼ 0.6%€-8k▼ 314%€-1k▲ 84.5%€-1k▼ 19.9%
Net result€1.33M-€931k▼ 29.8%€636k▼ 31.7%€1.23M▲ 93.1%€2.84M▲ 131%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €1k in 2025 against €1k in 2024; the loss grows.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €9.69M
Fixed assets
€9.69M▼ 5.1%
Current assets
€3k▼ 98.1%
Equity and liabilities €9.69M
Equity
€8.67M▼ 13.4%
Debt
€1.01M▲ 192%
The debt ratio rises from 3.4% to 10.5%. Equity is lower and debt is higher.
Key figures and ratios
Solvency
89.5%▼
2024 · 96.6%
Current ratio
0.00▼
2024 · 0.54
Quick ratio
0.00▼
2024 · 0.54
Debt / equity
0.12▲
2024 · 0.03
ROE
32.7%▲
2024 · 12.3%
ROA
29.3%▲
2024 · 11.9%
Debt
€1.01M▲
2024 · €347k
Debt ≤ 1 year
€959k▲
2024 · €294k
Income taxes
€-5k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€10.36M€9.69M▼
Fixed assets21/28€10.20M€9.69M▼
Financial fixed assets28€10.20M€9.69M▼
Current assets29/58€158k€3k▼
Amounts receivable within one year40/41€153k-
Other amounts receivable41€153k-
Cash at bank and in hand54/58€5k€3k▼
Equity and liabilities
Total equity and liabilities10/49€10.36M€9.69M▼
Equity10/15€10.01M€8.67M▼
Contributions10/11€8.43M€5.83M▼
Reserves13€1.59M€2.84M▲
Distributable reserves133€1.59M€2.84M▲
Amounts payable17/49€347k€1.01M▲
Amounts payable within one year42/48€294k€959k▲
Trade debts44€1k€7▼
Suppliers440/4€1k€7▼
Taxes, remuneration and social security45€5k-
Taxes450/3€5k-
Other amounts payable47/48€288k€959k▲
Accrued charges and deferred income492/3€54k€54k▲
Income statement
Code20242025
Other operating charges640/8€1k€1k▲
Operating profit (loss)9901€-1k€-1k▼
Financial income75/76B€1.28M€2.84M▲
Recurring financial income75€1.28M€2.84M▲
Financial charges65/66B€54k€1k▼
Recurring financial charges65€54k€1k▼
Profit (loss) for the period before taxes9903€1.23M€2.84M▲
Income taxes67/77-€-5k
Profit (loss) for the period9904€1.23M€2.84M▲
Profit (loss) for the period to be appropriated9905€1.23M€2.84M▲
Appropriation of the result
Profit (loss) to be appropriated9906€1.23M€2.84M▲
Transfer to equity691/2€1.23M€2.84M▲
To other reserves6921€1.23M€2.84M▲
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 31 days late
28-07
State Gazette act
Resignations & appointmentsBoard meeting · General meeting · Director appointment11 facts ▸
State Gazette act
Resignations & appointments
Board meeting · General meeting · Director appointment11 facts ▸
- Board meeting, 18/05/2026
- General meeting, 10/06/2026
- Director appointment, BV KST Pharma (bestuurder)
- Director appointment, BV KST Pharma (gedelegeerd bestuurder)
- Permanent representative, Koen Straetmans
- Director resignation, BV ALEXO (gedelegeerd bestuurder en bestuurder)
- Director discharge, BV ALEXO
- Director appointment, BV KST Pharma (bestuurder)
- Permanent representative, Olivier Delaere
- Permanent representative, Frank Coene
- Permanent representative, Eric Van Nueten
2025
31-12
Financial
Highest result since 2018net €2.84M ▲131%
Net result €2.84M, the highest in the series.
28-08
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 28 days late
2024
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 30 days late
2023
31-12
Financial
Weakest financial yearnet €636k ▼31.7%
Net result drops to €636k, the lowest in the series; recovery starts the following year.
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 31 days late
2022
27-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
14-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
22-06
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
31-12
Financial
Liquidity doublescurrent ratio 2.47
Current ratio from 1.21 to 2.47; short-term debt falls from €433k to €421k.
14-06
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
18-06
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
26-06
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 directors, no change since 2026
KST Pharma
CurrentDirector · since 18-05-2026 · Private limited company · perm. rep.: Koen Straetmans
18-05-2026
KST Pharma: Appointed as Director
18-05-2026
KST Pharma: Appointed as Managing director
18-05-2026
BV ALEXO: Resigned as Gedelegeerd bestuurder en bestuurder
Location & real-estate footprint
Registered office, Sint-Niklaas · 1 establishment unit since 2004
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Eigenlostraat 19100 Sint-NiklaasGround area
5,955 m²
Parcel 46442C1177/02D000, Flanders. Linked by address, not a title deed.
1 establishment unit
Febelcofonds
since 20042.135.714.425
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 46442C1177/02D000 | Flanders | 5,955 m² | - | - |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Connections & network
1 connected companyNetwork connections
Shared corporate director
→
Ownership & control
1 partyControl over this companysits on this company's board1
2 subsidiaries · 1 location
controls
FEBELCOFONDSBE 0479.158.422
Recognitions · licences · registrations
Legal Entity Identifier
699400S15W6Q2CDT4080
Company data · Crossroads Bank
Identification
Legal formCooperative company
Founded27-12-2002
Fiscal year end31-12
Sources
Crossroads Bank for EnterprisesNational Bank · 23 filingsAddress and cadastre registers
Data from official sources, last processed on 17-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
1 entryE-mail:aandeelhouders@febelcofonds.be